RQ 00310941Alternative Names: 5-HT 2B antagonist - RaQualia
Latest Information Update: 22 Apr 2016
At a glance
- Originator Pfizer Japan
- Developer RaQualia Pharma
- Class Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Serotonin 2B receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Irritable bowel syndrome